secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2022-06-01T23:59:59+00:00
Accession:  0001628280-22-015897
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion appoints J. Martin Carroll as Chairperson of the Board and new director
--------------------------------------------------------------------------------

- J. Martin Carroll appointed to fill newly created vacancy; board expands from 9 to 10 directors.
- Carroll named Chairperson of the Board effective June 1, 2022.
- Carroll previously served as President/CEO of Boehringer Ingelheim Corporation and Merck & Co. veteran.
- Esperion reiterates expectation for CLEAR Outcomes topline data in Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828022015897/0001628280-22-015897-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828022015897/espr-20220601.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-015897

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer